Table 1

Characteristics of patients with MRA treatment compared with patients with discontinued MRA treatment

Characteristics*Continued MRA (n=275)Discontinued MRA (n=297)P value
Female sex, n (%)71 (26)107 (36)0.008
Age, years72 ± (11)77 ± (12)<0.001
LVEF, %36 ± (8)37 ± (10)0.054
Medical history, n (%)
 Diabetes17 (8)12 (5)0.271
 Hypertension181 (66)216 (73)0.063
 Coronary artery disease†133 (49)151 (52)0.563
 CRT/CRT-D/ICD62 (23)71 (24)0.700
 Open heart surgery‡61 (22)81 (28)0.146
 Atrial fibrillation121 (44)161 (54)0.015
Physical examination
 Heart rate, bpm74 ± (16)75 ± (16)0.279
 Systolic BP, mm Hg123 ± (19)127 ± (20)0.036
 Diastolic BP, mm Hg73 ± (12)73 ± (12)0.635
 BMI, n (%)28 ± (6)27 ± (5)0.082
 NT-proBNP (ng/L) (median (IQR))979 (432–2481)1547 (573–3531)0.002
 S-haemoglobin, mmol/L134 ± (17)132 ± (17)0.120
 S-sodium, mmol/L139 ± (3)139 ± (3)0.458
 S-potassium, mmol/L4.4 ± (0.5)4.3 ± (0.5)0.242
eGFR, ml/min/1.73 m259 ± (17)50 ± (19)<0.001
Medications, n (%)
 ACEI/ARB/ARNI257 (94)267 (90)0.125
 Beta-blocker255 (93)268 (90)0.287
 Loop diuretic174 (63)202 (68)0.233
 Thiazide diuretic7 (3)8 (3)0.912
  • *Values are means and SD, no. (%) or median (IQR) when appropriate. P values are from the χ2, Student’s t-test, Mann-Whitney U test or Fisher’s exact test as appropriate.

  • †Coronary artery disease defined as either previous myocardial infarction or documented stenosis of ≥50%.

  • ‡Open heart surgery includes coronary artery bypass graft/heart valve surgery/other.

  • ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BMI, body mass index; BP, blood pressure; CRT, Cardiac Resynchronisation Therapy; CRT-D, CRT with defibrillator; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide.